MARKET

DTIL

DTIL

Precision Biosciences
NASDAQ
3.800
+0.230
+6.44%
After Hours: 3.761 -0.039 -1.04% 18:21 02/06 EST
OPEN
3.610
PREV CLOSE
3.570
HIGH
3.825
LOW
3.580
VOLUME
91.64K
TURNOVER
--
52 WEEK HIGH
8.82
52 WEEK LOW
3.530
MARKET CAP
91.47M
P/E (TTM)
-0.4523
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DTIL last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at DTIL last week (0119-0123)?
Weekly Report · 01/26 09:53
JonesTrading Keeps Their Buy Rating on Precision BioSciences (DTIL)
TipRanks · 01/23 12:56
Precision BioSciences 13G Filing Shows Empery Asset Management Reports 9.99% Stake In Co As Of December 31, 2025
Benzinga · 01/22 18:11
EMPERY ASSET MANAGEMENT LP REPORTS 9.99% PASSIVE STAKE IN PRECISION BIOSCIENCES AS OF DEC 31, 2025 - SEC FILING
Reuters · 01/22 18:06
Weekly Report: what happened at DTIL last week (0112-0116)?
Weekly Report · 01/19 09:57
Precision BioSciences Highlights 2026 Gene Editing Priorities
TipRanks · 01/13 21:28
Precision BioSciences Provides 2026 Business Update Emphasizing Progress In PBGENE-HBV And PBGENE-DMD Programs, Anticipated Clinical Data In 2026, And Strong $137M Cash Runway
Benzinga · 01/12 12:32
More
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.